Modulating sensory gating in healthy volunteers: The effects of ketamine and haloperidol

Biological Psychiatry

Volumn 52, Issue 9, 2002, Pages 887-895

  Oranje, Bob ^a,c   Gispen De Wied, Christine C ^a   Verbaten, Marinus Nicholaas ^a,b   Kahn, René S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Department of Psychopharmacology ^*  (Netherlands)

Author keywords

Haloperidol; Ketamine; P50 suppression; PPI; Sensory gating

Indexed keywords

HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PLACEBO;

ARTICLE; CHANNEL GATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG EFFECT; EVOKED RESPONSE; HUMAN; MALE; NORMAL HUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; REDUCTION; SCHIZOPHRENIA; SENSORY SYSTEM; STIMULUS RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; ELECTROOCULOGRAPHY; EVOKED POTENTIALS; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; HEART RATE; HOMOVANILLIC ACID; HUMANS; HYDROCORTISONE; KETAMINE; MALE; NEURONS, AFFERENT; NEUROTRANSMITTER AGENTS; PROLACTIN; SCHIZOPHRENIA; STARTLE REACTION;

EID: 0036839191     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01377-X     Document Type: Article

References (55)

1. Abduljawad K.A., Langley R.W., Bradshaw C.M., Szabadi E. Effects of bromocriptine and haloperidol on prepulse inhibition of the acoustic startle response in man. J Psychopharmacol. 12:1998;239-245.
2. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull. 24:1998;189-202.
3. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry. 17:1982;639-654.
4. Andreasen N.C., Flaum M., Arndt S. The comprehensive assessment of symptoms and history (CASH) An instrument for assessing psychopathology and diagnosis . Arch Gen Psychiatry. 49:1992;615-623.
5. Boutros N.N., Zouridakis G., Overall J. Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr. 22:1991;40-45.
6. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia Human and animal model studies . Arch Gen Psychiatry. 47:1990;181-188.
7. Braff D.L., Grillon C., Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry. 49:1992;206-215.
8. Braff D.L., Stone C., Callaway E., Geyer M., Glick I., Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology. 15:1978;339-343.
9. Braff D.L., Swerdlow N.R., Geyer M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry. 156:1999;596-602.
10. Breier A., Adler C.M., Weisenfeld N., Su T.P., Elman I., Picken L., et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects Application of a novel PET approach . Synapse. 29:1998;142-147.
11. Clementz B.A., Geyer M.A., Braff D.L. Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophr Res. 30:1998;71-80.
12. Cullum C.M., Harris J.G., Waldo M.C., Smernoff E. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res. 10:1993;131-141.
13. Domino E.F., Chodoff P., Corrsen G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther. 6:1965;279-291.
14. Duncan E.J., Madonick S.H., Parwani A., Angrist B., Rajan R., Chakravorty S., et al. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology. 25:2001;72-83.
15. Endicott J., Spitzer R.L. A diagnostic interview The schedule for affective disorders and schizophrenia . Arch Gen Psychiatry. 35:1978;837-844.
16. Freedman R., Adler L.E., Waldo M.C., Pachtman E., Franks R.D. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia Comparison of medicated and drug-free patients . Biol Psychiatry. 18:1983;537-551.
17. Freedman R., Waldo M.C., Bickford-Wimer P., Nagamoto H. Elementary neuronal dysfunctions in schizophrenia. Veterans Administration Medical Research Service Symposium on Biomedical Research in Schizophrenia (1989, Denver, Colorado). Schizophr Res. 4:1991;233-243.
18. Geisslinger G., Menzel Soglowek S., Kamp H.D., Brune K. Stereoselective high-performance liquid chromatographic determination of the enantiomers of ketamine and norketamine in plasma. J Chromatogr. 568:1991;165-176.
19. Geyer M.A., Braff D.L. Habituation of the blink reflex in normals and schizophrenic patients. Psychophysiology. 19:1982;1-6.
20. Geyer M.A., Braff D.L. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull. 13:1987;643-668.
21. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia A decade in review . Psychopharmacology (Berl). 156:2001;117-154.
22. Graham F.K. The more or less startling effects of weak prestimulation. Psychophysiology. 12:1975;238-248.
23. Grillon C., Ameli R., Charney D.S., Krystal J., Braff D.L. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol Psychiatry. 32:1992;939-943.
24. Grotta J., Clark W., Coull B., Pettigrew L.C., Mackay B., Goldstein L.B. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke. 26:1995;602-605.
25. Hazlett E.A., Buchsbaum M.S., Haznedar M.M., Singer M.B., Germans M.K., Schnur D.B. Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology. 35:1998;186-198.
26. Jentsch J.D., Tran A., Taylor J.R., Roth R.H. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system Behavioral and neurochemical evidence . Psychopharmacol (Berl). 138:1998;89-95.
27. Johansson C., Jackson D.M., Svensson L. The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology (Berl). 116:1994;437-442.
28. Johansson C., Jackson D.M., Zhang J., Svensson L. Prepulse inhibition of acoustic startle, a measure of sensorimotor gating Effects of antipsychotics and other agents in rats . Pharmacol Biochem Behav. 52:1995;649-654.
29. Karper L.P., Freeman G.K., Grillon C., Morgan C.A., Charney D.S., Krystal J.H. Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. J Neuropsychiatry Clin Neurosci. 8:1996;60-66.
30. Keith V.A., Mansbach R.S., Geyer M.A. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry. 30:1991;557-566.
31. Kenemans J.L., Molenaar P.C., Verbaten M.N., Slangen J.L. Removal of the ocular artifact from the EEG A comparison of time and frequency domain methods with simulated and real data . Psychophysiology. 28:1991;114-121.
32. Koch M. The neurobiology of startle. Prog Neurobiol. 59:1999;107-128.
33. Kumari V., Mulligan O.F., Cotter P.A., Poon L., Toone B.K., Checkley S.A., Gray J.A. Effects of single oral administrations of haloperidol and d- amphetamine on prepulse inhibition of the acoustic startle reflex in healthy male volunteers. Behav Pharmacol. 9:1998;567-576.
34. Kumari V., Soni W., Mathew V.M., Sharma T. Prepulse inhibition of the startle response in men with schizophrenia - effects of age of onset of illness, symptoms, and medication. Arch Gen Psychiatry. 57:2000;609-614.
35. Kumari V., Soni W., Sharma T. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry. 156:1999;1046-1051.
36. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
37. Lipton S.A., Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 330:1994;613-622.
38. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug Sernyl . Arch Neurol Psychiatry Chicago. 81:1959;363-369. [see comments].
39. Luby E.D., Gottlieb J.S., Cohen B.D., Rosenbaum G., Domino E.F. Model psychoses and schizophrenia. Am J Psychiatry. 119:1962;61-67.
40. Mansbach R.S., Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology. 2:1989;299-308.
41. Mansbach R.S., Geyer M.A. Parametric determinants in pre-stimulus modification of acoustic startle Interaction with ketamine . Psychopharmacology. 105:1991;162-168.
42. Martinez Z.A., Oostwegel J., Geyer M.A., Ellison G.D., Swerdlow N.R. "Early" and"late" effects of sustained haloperidol on apomorphine- and phencyclidine-induced sensorimotor gating deficits. Neuropsychopharmacology. 23:2000;517-527.
43. McGhie A., Chapman J. Disorders of attention and perception in early schizophrenia. Br J Med Psychol. 34:1961;103-116.
44. Nagamoto H.T., Adler L.E., Hea R.A., Griffith J.M., McRae K.A., Freedman R. Gating of auditory P50 in schizophrenics Unique effects of clozapine . Biol Psychiatry. 40:1996;181-188.
45. Nagamoto H.T., Adler L.E., Waldo M.C., Freedman R. Sensory gating in schizophrenics and normal controls Effects of changing stimulation interval . Biol Psychiatry. 25:1989;549-561.
46. Nagamoto H.T., Adler L.E., Waldo M.C., Griffith J. Gating of auditory response in schizophrenics and normal control Effects of recording site and stimulation interval on the P50 wave . Schizophr Res. 4:1991;31-40.
47. Oranje B, Oel CJ, Gispen de Wied CC, Verbaten MN, Kahn RS (2002): Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. J Clin Psychopharmacol 22:359-365.
48. Oranje B., Van Berckel B.N.M., Kemmer C., van Ree J.M., Kahn R.S., Verbaten M.N. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology. 22:2000;293-302.
49. Pietraszek M., Ossowska K. Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats. Naunyn Schmiedebergs Arch Pharmacol. 357:1998;466-471.
50. Smith G.S., Schloesser R., Brodie J.D., Dewey S.L., Logan J., Vitkun S.A., et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology. 18:1998;18-25.
51. Swerdlow N.R., Caine S.B., Braff D.L., Geyer M.A. The neural substrates of sensorimotor gating of the startle reflex A review of recent findings and their implications . J Psychopharmacol. 6:1992;176-190.
52. van Berckel B.N., Oranje B., van Ree J.M., Verbaten M.N., Kahn R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology Berl. 137:1998;271-281.
53. Venables PH (1964). Input dysfunction in schizophrenia. In: BA Mahler, editor. Progress in Experimental Personality Research, Volume 1. New York, NY: Academic Press, pp 1-47.
54. Ward P.B., Hoffer L.D., Liebert B.J., Catts S.V., O'Donnell M., Adler L.E. Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Res. 64:1996;121-135.
55. Westenberg H.G., Verhoeven W.M. CSF monoamine metabolites in patients and controls Support for a bimodal distribution in major affective disorders . Acta Psychiatrica Scand. 78:1988;541-549.